Chimeric receptor-binding domain vaccine design and sequential immunization enhanced broadly neutralizing antibody responses against COVID-19
Overall, RBDco can induce bnAbs in animals via chimeric RBDs with the SARS-CoV-2 VOC in different lineages and is a candidate for mRNA vaccine for a rapid response to viral mutations.
Authors
- Chunlai Jiang (ORCID: https://orcid.org/0000-0002-4497-5315)
- Wenjing Teng
- Xin Tang (ORCID: https://orcid.org/0000-0002-0155-4967)
- Yang Zang (ORCID: https://orcid.org/0000-0002-7936-5875)
- Hualong Xi
- Yang Xiao (ORCID: https://orcid.org/0000-0002-0516-0543)
- Yan Lu (ORCID: https://orcid.org/0000-0002-8370-4059)
- Ying Sun (ORCID: https://orcid.org/0009-0008-7911-9034)
- Wei Peng (ORCID: https://orcid.org/0000-0001-7011-0035)
Institutions
- Jilin University (CN)
- Regend Therapeutics (China) (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-27
- DOI
- https://doi.org/10.3389/fimmu.2025.1543212
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.40